Vertex (VRTX) PT Raised to $210 at Baird

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. LYB
2. RELIANCE:I
3. BP
4. CL
5. OKTA
6. NWG
7. NWG:LN
8. REGN
9. RDDT
10. CIFR

Go back to Vertex (VRTX) PT Raised to $210 at Baird

Vertex Pharma (VRTX) Confirms FDA Approves TRIKAFTA to Treat Underlying Cause of CF in People Ages 12 and Older Who Have at Least One F508del Mutation

October 21, 2019 3:56 PM EDT

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance... More

FDA approves Vertex's (VRTX) new breakthrough therapy for cystic fibrosis

October 21, 2019 2:51 PM EDT

The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.

At the FDA, were consistently looking for ways to help speed the development of new therapies for complex diseases, while maintaining our high standards of review. Todays landmark approval is... More